This medicine is subject to additional monitoring. This will allow quick identification
of new safety information. You can help by reporting any side effects you may get.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems .
Consumer Medicine Information
What is in this leaflet
This leaflet answers some common questions about MYLOTARG. It does not contain all
the available information. It does not take the place of talking to your doctor or
All medicines have risks and benefits. Your doctor has weighed the risks of you taking
MYLOTARG against the benefits they expect it will have for you.
If you have any concerns about taking this medicine, ask your doctor or pharmacist.
Keep this leaflet with the medicine.
You may need to read it again.
What MYLOTARG is used for
MYLOTARG contains the active ingredient gemtuzumab ozogamicin. It belongs to a group
of medicines called antineoplastic agents that target cancer cells.
MYLOTARG is used to treat patients aged 15 years and above with acute myeloid leukaemia
(AML). AML is a cancer of the blood and bone marrow in which the bone marrow makes
immature white blood cells in high numbers. These abnormal cells crowd the bone marrow,
preventing it from making normal blood cells.
This medicine works by stopping the abnormal growth of these cells and destroying
Ask your doctor if you have any questions about why this medicine has been prescribed
Your doctor may have prescribed it for another reason.
This medicine is available only with a doctor's prescription.
Before you are given MYLOTARG
When you must not be given it
Do not receive MYLOTARG if you have an allergy to:
any medicine containing gemtuzumab ozogamicin
any of the ingredients listed at the end of this leaflet.
Some of the symptoms of an allergic reaction may include:
shortness of breath
wheezing or difficulty breathing
swelling of the face, lips, tongue or other parts of the body
rash, itching or hives.
Do not receive this medicine if you are pregnant.
It may affect your developing baby if you take it during pregnancy.
Do not breast-feed if you are receiving this medicine.
It is not known if MYLOTARG passes into breast milk and there is a possibility that
your baby may be affected.
MYLOTARG should not be used in children and adolescents under 15 years of age.
Limited information is available on MYLOTARG treatment in these patients.
Do not receive this medicine after the expiry date printed on the pack or if the packaging
is torn or shows signs of tampering.
If you are not sure whether you should start receiving this medicine, talk to your
Before you start to be given it
Tell your doctor if you have allergies to any other medicines, foods, preservatives
Tell your doctor if you have or have had any of the following medical conditions:
MYLOTARG may cause, during or after treatment, a potentially life-threatening condition
called hepatic venoocclusive disease, in which the blood vessels in the liver become
damaged and obstructed by blood clots which may include fluid retention, rapid weight
gain, increased liver size (which may be painful), and ascites (excessive accumulation
of fluid in the abdominal cavity).
an infusion reaction
Tell your doctor if you have had any of the following symptoms during or shortly after
being given MYLOTARG
fever, chills, hot flush, dizziness or lightheadedness, rash or trouble breathing
nausea, vomiting, diarrhoea, changes in heartbeat, decreased urine or blood in urine,
muscle weakness or cramps.
Tell your doctor if you are pregnant or plan to become pregnant or are breast-feeding.
It is unlikely that you will be given this medicine if you are pregnant or trying
to become pregnant, as it may harm your unborn baby. Your doctor can discuss with
you the risks and benefits involved.
You must avoid becoming pregnant or fathering a child if you are receiving MYLOTARG.
It is not known whether this medicine passes into breast milk.
You must not breast-feed during treatment with MYLOTARG and for at least 1 month after
your last dose.
Seek advice from your doctor regarding fertility preservation before treatment.
Fertility may be compromised by treatment with MYLOTARG.
If you have not told your doctor about any of the above, tell him/her before you start
Taking other medicines
Tell your doctor or pharmacist if you are taking any other medicines, including:
all prescription medicines
all medicines, vitamins, herbal supplements or natural therapies you buy without a
prescription from a pharmacy, supermarket, naturopath or health food shop.
Some medicines may be affected by MYLOTARG or may affect how well it works. You may
need different amounts of your medicines, or you may need to take different medicines.
Your doctor will advise you.
How MYLOTARG is given
MYLOTARG is given in "cycles". The first MYLOTARG treatment cycle is made up of a
single MYLOTARG dose given on Day 1, Day 4 and Day 7 in Week 1 (Induction cycle).
The second and third MYLOTARG treatment cycles are made up of a single MYLOTARG dose
given on Day 1 (Consolidation cycle).
A doctor or nurse will give you your MYLOTARG dose gradually over 2 hours through
a drip in your vein (intravenous infusion).
How much is given
Your doctor will calculate how much you need to be given.
This will depend on your height and weight and may also depend on your condition and
how you have responded to previous treatment.
Medicines given before each cycle
Before each treatment with MYLOTARG you will be given other medicines (premedication)
to help reduce symptoms such as fever, chills or hot flush, known as infusion reactions,
and other possible side effects.
How long it is given
You will receive between one and three cycles of MYLOTARG in combination with chemotherapy.
The first cycle is called Induction. The second and third cycles are called Consolidation.
If the medicine works well after the Induction cycle, you may receive the two Consolidation
cycles. If you do not respond to the medicine after the first cycle your treatment
will be stopped.
Your doctor will discuss with you how long your treatment will last.
If you forget a treatment
If you miss a treatment, contact your doctor or nurse as soon as possible to make
a new appointment.
If you take too much (overdose)
It is unlikely that you will be given too much MYLOTARG, as your dose will be calculated
and given to you in a specialised setting under the supervision of a doctor.
If an overdose is suspected, immediately telephone your doctor or Poisons Information
Centre (telephone 13 11 26) for advice, or go to Accident and Emergency at the nearest
You may need urgent medical attention.
While you are being given MYLOTARG
Things you must do
If you (or your partner) become pregnant while you are being given this medicine,
tell your doctor immediately.
You must avoid becoming pregnant or fathering a child.
Use a proven method of birth control (contraception) during treatment with MYLOTARG
if you can become pregnant or if you can father a child.
You must continue to use 2 methods of effective contraception during treatment and
for at least 7 months (women) or at least 4 months (men) after the last dose of MYLOTARG.
If you are about to be started on any new medicine, tell your doctor and pharmacist
that you are being treated with MYLOTARG.
Tell all doctors, dentists and pharmacists who treat you that you are being given
If you are going to have surgery, tell the surgeon or anaesthetist that you are being
given this medicine.
It may affect other medicines used during surgery.
If you are about to have any blood tests, tell your doctor that you are taking this
It may interfere with the results of some tests.
Keep all of your doctor's appointments so that your progress can be checked.
Your doctor will take regular blood tests to make sure MYLOTARG is working and to
check for side effects.
In particular, your blood counts and liver function will need to be checked before
Your doctor will also monitor you for signs and symptoms of infection, bleeding and
Your doctor may change your dose, interrupt or completely stop treatment with this
medicine if you have certain side effects.
Your doctor may also lower your dose based on your response to treatment.
Things to be careful of
Be careful driving or operating machinery until you know how MYLOTARG affects you.
This medicine may cause fatigue in some people. If you feel tired, do not drive, operate
machinery or do anything else that could be dangerous.
If you feel light-headed, dizzy or faint when getting out of bed or standing up, get
Standing up slowly, especially when you get up from bed or chairs, will help your
body get used to the change in position and blood pressure. If this problem continues
or gets worse, talk to your doctor.
Tell your doctor or pharmacist as soon as possible if you do not feel well while you
are receiving MYLOTARG.
All medicines can have side effects. Sometimes they are serious, most of the time
they are not. You may need medical attention if you get some of the side effects.
Do not be alarmed by this list of possible.
You may not experience any of them.
Ask your doctor or pharmacist to answer any questions you may have.
Tell your doctor or nurse immediately or go to Accident and Emergency at your nearest
hospital if you notice any of the following:
rapid weight gain, pain in the upper right side of your abdomen (stomach), swelling
of your abdomen
These could be symptoms of a very serious and potentially fatal condition called venoocclusive
If you receive MYLOTARG either before or after a stem cell transplant (a process that
involves replacing blood-forming cells called stem cells that are diseased or have
been damaged by anti-cancer medicines) you have an increased chance of getting this
If you have abnormal liver function you may have an increased chance of getting this
fever, chills, hot flush, dizziness or lightheadedness, rash or trouble breathing
during or shortly after the MYLOTARG infusion (infusion-related reactions)
shortness of breath, wheezing, coughing, difficulty breathing, changes in the colour
of your skin to a blue tinge, feeling of heaviness or congestion in lungs
fever, sweating and chills
These could be signs of an infection which may be serious and potentially fatal.
bruising easily or getting nose bleeds on a regular basis
symptoms in the stomach and intestines (for example, nausea, vomiting, diarrhoea),
heart (for example, changes in the rhythm), kidney (for example, decreased urine,
blood in urine), and nerves and muscles (for example, muscle spasms, weakness, cramps)
These could be signs of a serious condition known as tumour lysis syndrome, which
is caused by chemical disturbances in the blood due to the breakdown of dying cancer
The above list includes very serious side effects. You may need urgent medical attention
Tell your doctor as soon as possible if you notice any of the following:
fatigue and shortness of breath
pain in the abdomen.
The above list includes signs of serious side effects that may require urgent medical
Tell your doctor or nurse if you notice any of the following:
nausea (feeling sick)
mouth ulcer, redness or pain
high or low blood pressure
skin itching, redness, rash or blistering
irregular or racing heart rhythm
high blood sugar
a yellowish colour of the skin, eyes, and other tissues.
The above list includes the more common side effects of your medicine.
Some side effects (for example, changes in your liver function) can only be found
when your doctor does tests from time to time to check your progress.
Tell your doctor or pharmacist if you notice anything that is making you feel unwell.
Other side effects not listed above may also occur in some people.
After receiving MYLOTARG
MYLOTARG must be kept in the original packaging in a refrigerator, protected from
light, before it is time to use it.
Your doctor, nurse or pharmacist will prepare the infusion for you before you are
Your doctor, nurse and pharmacist have more information on how to store and prepare
Your doctor, nurse or pharmacist will dispose of any left-over medicine.
What it looks like
MYLOTARG is a white or off-white powder or cake supplied in a glass vial.
Before MYLOTARG is given, the powder is mixed with sterile water and diluted with
a solution of sodium chloride.
Each MYLOTARG carton contains 1 vial.
MYLOTARG contains 5 mg of gemtuzumab as the active ingredient.
dibasic sodium phosphate
monobasic sodium phosphate monohydrate
This medicine contains less than 1 mmol sodium (23 mg) per dose.
MYLOTARG is supplied in Australia by:
Pfizer Australia Pty Ltd
Toll Free Number: 1800 675 229
® Registered Trademark
© Pfizer Australia Pty Ltd
This leaflet was prepared in January 2022.
AUST R 316671